ENTPD1 and head and neck cancer: Higher frequencies of CD39+CD103+CD8+ TILs in patients with head and neck cancer were associated with better overall survival, and in vitro studies showed that co-expression of CD39 and CD103 were strongly enriched in tumor-recognizing and -killing CD8 T cells (44).